
Stimulating insulin secretion from the pancreas when glucose levels are elevated
Inhibiting glucagon release, preventing excess glucose production by the liver
Slowing gastric emptying, leading to prolonged digestion and steadier blood sugar levels

Available as Victoza (for diabetes) and Saxenda (for weight management)
Available as Ozempic (for diabetes) and Wegovy (for weight management)
Available as Mounjaro (for diabetes and weight management)
GLP-1 agonists effectively lower blood sugar by stimulating insulin secretion and curbing glucose production from the liver. These medications are commonly used when other treatments like metformin are not sufficient for controlling blood glucose levels. Some GLP-1 agonists have also shown positive effects in reducing the risk of cardiovascular events for people with type 2 diabetes and heart disease.
GLP-1 agonists like Wegovy and Saxenda are approved for weight loss in people without diabetes. These medications help reduce appetite and increase feelings of fullness, making it easier for individuals to eat less. Research indicates that combining GLP-1 therapy with lifestyle changes can result in significant weight loss that is both effective and long-lasting.
GLP-1 receptor agonists help control blood glucose by stimulating insulin secretion in response to meals and reducing glucagon production. This dual mechanism leads to better blood sugar regulation and fewer post-meal glucose spikes. As the effect is glucose-dependent, the risk of hypoglycemia is lower than with other diabetes medications, making GLP-1 therapy a safer option for long-term diabetes management.
One of the significant benefits of GLP-1 therapy is its ability to help with sustainable weight loss. By slowing gastric emptying and signaling satiety, these medications help curb appetite and reduce calorie intake. Clinical trials show that medications like liraglutide, semaglutide, and tirzepatide result in substantial weight loss, which is often maintained with lifestyle modifications.



GLP-1/GIP co-agonists activate both GLP-1 and GIP receptors, improving insulin release and reducing appetite more effectively than GLP-1 alone. These medications offer a comprehensive solution to managing blood sugar and hunger in individuals with obesity and type 2 diabetes.
GLP-1/glucagon co-agonists help with fat loss while preserving lean muscle, offering a balanced approach to improving metabolism and weight management.

